ASHG 2026 has ended. This guide stays up as the record of who was there. Next: ASHG 2027, Oct 26–30, 2027 in Nashville

AstraZeneca at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

AstraZeneca brings 5 presentations to ASHG 2026 in Montréal. Its program centres on rare disease genetics, population-scale genomics and therapeutic discovery. Its presentations assess rare variants in nearly 500,000 UK Biobank genomes and link serum alkaline phosphatase genetics to hypophosphatasia symptoms.

OrganizationASHG 2026 Attendance
AstraZeneca
Cambridge, UK
1 Senior Data Scientist · 1 Associate Principal Scientist (Centre of Genomics Research) · 1 Associate Principal Scientist · 1 Senior Biostatistician and Data Scientist
Public company~96,100 people
Develops and commercialises prescription medicines for patients across oncology, rare diseases, cardiovascular-renal-metabolic, and respiratory-immunology indications.
AstraZeneca completed a global license agreement acquiring worldwide rights to develop and commercialize Zegfrovy.
›
AstraZeneca completed a global license agreement acquiring worldwide rights to develop and commercialize Zegfrovy.
2026-09 · source
AstraZeneca strengthened its weight-management portfolio through a new collaboration with CSPC Pharmaceuticals on obesity and diabetes therapies.
2026-01 · source
AstraZeneca named Rick Suarez senior VP and head of its US BioPharmaceuticals business, a new US leadership contact.
2026-01 · source
Source: company newsroom
Q2 2026 revenue $15.38B, up 6%
›
FY2026 guidance reconfirmed for mid-to-high single-digit revenue growth and low double-digit EPS growth. · 2026-07-27
“Total Revenue 30,672 9 6 15,384 6 5. At CER, Total Revenue is expected to increase by a mid-to-high single-digit %.”
Source: results release
Currently hiring: 668 open roles
›
Source: careers page
Poster
Wed Oct 21
2:30 pm
A population-scale assessment of rare long non-coding RNA variants in human disease using ~500,000 UK Biobank whole-genome sequences
Rare variantsBioinformaticsNon-coding RNAStatistical genetics
Poster
Thu Oct 22
4:15 pm
Multi-omics non-coding variant prioritization and phenome-wide discovery with JARVIS2
Collaborators: The University of Melbourne, Baylor College of Medicine
Variant interpretationMachine learningPhenome-wide associationQuantitative trait
Poster
Thu Oct 22
4:15 pm
MILTON v2: Multi-omics and time-to-diagnosis prediction in UK Biobank enhances disease risk stratification and genetic discovery across diverse populations
Collaborators: University of Cambridge, The University of Melbourne
Machine learningLarge-scale biobanksRisk assessmentMulti-omics
Poster
Thu Oct 22
4:15 pm
Coverage-aware exact testing improves calibration and yields more discoveries in a heterogeneous exome cohort
Phenome-wide associationStatistical geneticsGenetic testing

Explore the full ASHG 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Montréal. Leave your work email and we’ll be in touch.

Privacy

Download the full ASHG 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at AstraZeneca

Tell us what you sell and we’ll find the people at AstraZeneca most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction